help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1479
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
92/4/1237    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kauhanen, S.
Right arrow Articles by Nuutila, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kauhanen, S.
Right arrow Articles by Nuutila, P.
Related Collections
Right arrow Diabetes and Insulin
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 4 1237-1244
Copyright © 2007 by The Endocrine Society

Fluorine-18-L-Dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography as a Tool to Localize an Insulinoma or ß-Cell Hyperplasia in Adult Patients

Saila Kauhanen, Marko Seppänen, Heikki Minn, Risto Gullichsen, Anna Salonen, Kalle Alanen, Riitta Parkkola, Olof Solin, Jörgen Bergman, Timo Sane, Jorma Salmi, Matti Välimäki and Pirjo Nuutila

Turku PET Centre (S.K., M.S., A.S., R.P., P.N.), and Departments of Surgery (S.K., R.G.), Oncology and Radiotherapy (H.M.), and Pathology (K.A.), Turku University Hospital, FIN-20520 Turku, Finland; Turku PET Centre (O.S., J.B.), Radiopharmaceutical Chemistry Laboratory, University of Turku, FIN-20520 Turku, Finland; Department of Medicine (T.S., M.V.), Helsinki University Hospital, FIN-00029 Helsinki, Finland; and Department of Medicine (J.S.), Tampere University Hospital, FIN-33014 Tampere, Finland

Address all correspondence and requests for reprints to: Pirjo Nuutila, M.D., Turku PET Centre, Turku University Hospital, P.O. Box 52, FIN-20521 Turku, Finland. E-mail: pirjo.nuutila{at}tyks.fi.

Context and Objective: Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) is a promising method in localizing neuroendocrine tumors. Recently, it has been shown to differentiate focal forms of congenital hyperinsulinism of infancy. The current study was set up to determine the potential of 18F-DOPA PET in identifying the insulin-secreting tumors or ß-cell hyperplasia of the pancreas in adults.

Patients and Methods: We prospectively studied 10 patients with confirmed hyperinsulinemic hypoglycemia and presumed insulin-secreting tumor using 18F-DOPA PET. Anatomical imaging was performed with computed tomography (CT) and magnetic resonance imaging (MRI). All patients were operated on, and histological verification was available in each case. Semiquantitative PET findings in the pancreas using standardized uptake values were compared to standardized uptake values of seven consecutive patients with nonpancreatic neuroendocrine tumors.

Results: By visual inspection of 18F-DOPA PET images, it was possible in nine of 10 patients to localize the pancreatic lesion, subsequently confirmed by histological analysis. 18F-DOPA uptake was enhanced in six of seven solid insulinomas and in the malignant insulinoma and its hepatic metastasis. Two patients with ß-cell hyperplasia showed increased focal uptake of 18F-DOPA in the affected areas. As compared to CT or MRI, 18F-DOPA PET was more sensitive in localizing diseased pancreatic tissue.

Conclusion: 18F-DOPA PET was useful in most patients with insulinoma and negative CT, MRI, and ultrasound results. In agreement with previous findings in infants, preoperative 18F-DOPA imaging seems to be a method of choice for the detection of ß-cell hyperplasia in adults. It should be considered for the detection of insulinoma or ß-cell hyperplasia in patients with confirmed hyperinsulinemic hypoglycemias when other diagnostic work-up is negative.




This article has been cited by other articles:


Home page
JNMHome page
P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans, and K. Y. Gulenchyn
6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications
J. Nucl. Med., April 1, 2008; 49(4): 573 - 586.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. T. Hardy, M. Hernandez-Pampaloni, J. R. Saffer, J. S. Scheuermann, L. M. Ernst, R. Freifelder, H. Zhuang, C. MacMullen, S. Becker, N. S. Adzick, et al.
Accuracy of [18F]Fluorodopa Positron Emission Tomography for Diagnosing and Localizing Focal Congenital Hyperinsulinism
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4706 - 4711.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society